Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sangamo Therapeutics (SGMO) Tax Provisions (2016 - 2025)

Sangamo Therapeutics (SGMO) has 8 years of Tax Provisions data on record, last reported at -$161000.0 in Q3 2025.

  • For Q3 2025, Tax Provisions fell 282.95% year-over-year to -$161000.0; the TTM value through Sep 2025 reached -$442000.0, down 3583.33%, while the annual FY2024 figure was -$167000.0, 96.71% up from the prior year.
  • Tax Provisions reached -$161000.0 in Q3 2025 per SGMO's latest filing, down from $27000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.3 million in Q3 2023 and bottomed at -$6.3 million in Q2 2023.
  • Average Tax Provisions over 5 years is -$238157.9, with a median of $74000.0 recorded in 2024.
  • The widest YoY moves for Tax Provisions: up 2066.67% in 2023, down 7782.93% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$67000.0 in 2021, then surged by 441.79% to $229000.0 in 2022, then tumbled by 218.78% to -$272000.0 in 2023, then tumbled by 56.99% to -$427000.0 in 2024, then surged by 62.3% to -$161000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were -$161000.0 in Q3 2025, $27000.0 in Q2 2025, and $119000.0 in Q1 2025.